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Abstract The ciliopathies are a class of rare human genetic
disease whose aetioligies lie in defective primary cilia.
Typical ciliopathies include Bardet–Biedl syndrome (BBS),
nephronophthisis (NPHP), Jeune, Joubert, oro-facial-digital
(OFD1) and Meckel (MKS) syndromes. All ciliopathies
have the common denominator of renal disease, often
including tubular cysts. In this study, we have modelled a
range of ciliopathies in zebrafish and shown in all cases that
knocking down these genes causes cystic lesions in the
kidney. We have identified two drugs, rapamycin and
roscovitine, which ameliorate the renal phenotype, both
morphologically and functionally. This is the first study in
which zebrafish has been used to identify potential
therapeutic modalities for ciliopathic renal disease, and the
results pave the way for further investigations in mamma-
lian models.
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Introduction
Primary cilia function to detect signalling molecules and
mechanical stimuli, such as fluid flow. Mutations in genes
encoding some of the approximately 1000 ciliary proteins
cause ciliopathies. Renal disease is a common denominator
of ciliopathies, often presenting with tubular cysts, lobula-
tion and clubbing [1, 2]. Published mouse models exist for
several ciliopathy genes (Bbs1, 2, 4, 6; Ofd1; Alms1, Pkhd),
and they develop renal cysts but often not until several
months of age [3].
The zebrafish is developing as a valid model for
investigating human cystic kidney diseases [4]. The zebra-
fish pronephros develops after 2 days post-fertilisation
(dpf), and the presence of cysts is easily screened at 3 dpf.
These cysts often compromise renal function, resulting in
body oedema by 4 dpf. Transparency of the embryos makes
morphological scoring rapid, and the large clutches enables
scalability. Ex vivo development allows therapeutic com-
pounds to be added directly to the water in which the eggs
are incubated [5]. Our aim is to create fish models for most
of the known human ciliopathies, screen them for a kidney
phenotype and then try to identify compounds that could
prevent cyst formation and potentially restore function.
Methods
Between 2 and 4.5 ng of translation and splice-blocking
morpholino oligonucleotides (MOs) (Gene Tools, Philomath,
OR) were used against the following genes (disease caused by
human mutations in brackets): bbs4, bbs6, bbs8 (Bardet–
Biedl syndrome); nphp2 (nephronophthisis); nphp5 (Senior–
Loken syndrome); nphp6 (Joubert syndrome); mks1, mks3
(Meckel syndrome); ofd1 (oro-facial-digital syndrome type
I). The MO sequences are available on request. Renal lesion
sizes were quantified by drawing an outline on a lateral
image of the swelling at 5 dpf using AXIOIMAGER ver. 4.4
software (Carl Zeiss Microimaging, Thornwood, NY).
Rapamycin (2–100 nM; Sigma, St. Louis, MO) and
roscovitine (5–100 μM; Sigma) were dissolved in 1%
DMSO and added directly to fish water at 24 hpf. Controls
were treated with DMSO only. For the functional assay,
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embryos were injected with MO or control MO and,
24 h later, treated with drug or vehicle. At 72 hpf, they
were anaesthetised in tricaine, immobilised in 2.5%
methyl cellulose, and 1 nl of 10-kDa rhodamine–dextran
(Invitrogen, Carlsbad, CA) was injected into the pericar-
dium. Images of the fluorescent embryos were collected at
1, 3, and 24 h post-injection. A region of 100×100 pixels
containing the heart was selected , and the fluorescence
intensity measured using IMAGEJ software (available at:
http://rsb.info.nih.gov/ij). At least ten embryos were mea-
sured for each treatment, and average fluorescent intensity
at each timepoint was measured. The percentage of
fluorescence remaining after 24 hpf was used to determine
the efficiency of renal filtration.
Results
We recently showed that mutations in a core intraflagellar
transport (IFT) gene, IFT80, cause Jeune syndrome, a
ciliopathy featuring skeletal dysplasia, renal cysts, polydac-
tyly and situs inversus [6]. The zebrafish morphant showed
cystic kidneys, random body situs (our unpublished data)
and a down-turned body-axis; all features reminiscent of
bona fide ciliary mutants. Other previously published
zebrafish ciliopathy morphants, including bbs4, bbs6 and
nphp2, also show similar phenotypes [7, 8].
Given the recapitulation of kidney anomalies in the ift80
fish model, we extended our study to include other
representative ciliopathy candidates, such as Bardet–Biedl
syndrome genes bbs4, bbs6 and bbs8; Meckel syndrome
genes mks1 and mks3; oro-facial-digital gene ofd1 and the
nephronophthisis genes nphp2, nphp5 and nphp6. Injection
of all these MOs into zebrafish produced a visible cyst in the
kidney by 3 dpf (see [6] for ift80; data not shown for others)
and severe oedema by 5 dpf (Fig. 1a–h). The efficiency of
knockdown was validated by reverse transcriptase (RT)-PCR
(not shown), and specificity proven by phenotypic rescue by
coinjection with mouse Ift80 mRNA (see [3]).
Several drugs have been shown to retard or reverse the
growth of kidney cysts, but none have ever been tested in
trials for the treatment of ciliopathy-associated renal
disease. The anti-proliferative rapamycin is a small mole-
cule inhibitor of the mTOR pathway [9]. mTOR interacts
with the C-terminus of polycystin-1 (PC1), a protein
mutated in autosomal dominant polycystic kidney disease
which localises to the cilium [10]. We reasoned that
rapamycin might be a good candidate to test on our
ciliopathy models and hypothesised that dysfunction of
ciliopathy proteins could result in the mislocalisation of
PC1 and consequent inappropriate activation of mTOR in
the kidney. If this were the case, then rapamycin would
ameliorate cyst formation in our morphants.
To test this, we added 10 nM rapamycin to the zebrafish
water at 24 hpf. The addition of rapamycin to uninjected
controls had no effect (Fig. 1a,a′). The left-hand column of
Fig. 1 (Fig. 1a–g) shows renal oedema at 5 dpf in every
ciliopathy morphant tested that had been treated with vehicle
(DMSO) alone. The right-hand column (Fig. 1a′–g′) shows
how every morphant treated with rapamycin shows almost
complete restoration of renal size and morphology. This is
quantified in Fig. 1i where the size of the oedematous
swelling is measured with and without rapamycin for all
morphants tested. The other phenotypes caused by the MO
(curly tail, cardiac oedema, otolith defects) are unaffected by
the addition of rapamycin, suggesting a kidney-specific
effect.
In the absence of rapamycin, 100% of mks1 morphants,
the mutations of which are lethal in humans, died by 5 dpf
and necrosed (Fig. 1f). However, upon the addition of
rapamycin, 75% of mks1 morphants survived (Fig. 1f′).
This suggests that rapamycin was able to prevent the early
lethality of mks1 morphants.
We extended the study to include roscovitine, a cyclin-
dependent kinase inhibitor recently shown to inhibit cyst
progression in murine models of polycystic kidney disease
[11]. The addition of roscovitine at 6 hpf caused embryos to
die before the tail-bud stage due to widespread apoptosis
(data not shown). When roscovitine was added at 24 hpf,
we observed partial amelioration of the renal phenotype and
cardiac oedema (Fig. 1h). Figure 1j shows that roscovitine
reduced the size of swelling in the kidney in a dose-
dependent fashion, but the effect is far less dramatic than
with rapamycin.
It is clear that roscovitine and rapamycin were able to
rescue the oedema caused by the cysts. That rapamycin
rescued the lethality of the mks1 morphants suggests that it
also has some positive effect on renal function. To assay the
effect on renal function, we adapted the protocol of
Hentschel et al. [12]. We injected the hearts of control
and morphant embryos, both treated and untreated with
drugs, with rhodamine-labelled 10-kDa dextran and fol-
lowed the passage of fluorescent dextran out of the embryo.
If kidney function is normal, the dextran will be filtered
through the glomerulus and excreted in the urine, resulting
in a disappearance of fluorescence 24 h after injection. This
was apparent in control embryos (Fig. 1k,k′ and m,m′), but
in ift80 morphants only around 50% of the dextran was
excreted from the embryo, indicating a 50% loss of
filtration capacity (Fig. 1l,l′ and n,n′).
An accumulation of dextran in the pronephric duct
implies a backing-up in the pronephros, likely due to a
reduced ability to filter the bloodstream (Fig. 1n′). This
impairment of filtration is unlikely to be a secondary effect
of compromised circulation as the dextran had diffused into
the peripheral vasculature of the morphant embryos just as
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Fig. 1 a, a′ Addition of 10 nM rapamycin (Rapa) to control zebrafish
has no effect on morphology at 5 dpf. Asterisk indicates the swim
bladder (not visible in morphant embryos). b–e′ bbs6, bbs8, nphp2 and
nphp6 all show a dramatic reduction in kidney oedema (outlined)
following the addition of Rapa. Other morphological phenotypes are
unaffected by the treatment. f, f′ mks1 morphants all die by 5 dpf
without Rapa, but 75% survive and show reduced kidney swelling after
the addition of Rapa. g, g′ ift80 morphant kidney phenotype is also
reversed by Rapa. Note that the pericardial oedema and curved body
axis are unaffected by the drug. h Roscovitine (Rosc) also reduces the
size of the kidney swelling but to a much lesser extent than Rapa. It also
appears to ameliorate some of the cardiac oedema. i Graph showing the
lateral surface area of the kidney oedema with and without Rapa for all
ten genes knocked down. In all cases, the addition of Rapa reduced the
kidney to levels similar to that of the controls. j Addition of a range of
Rosc concentrations to ift80 morphants shows dosage-dependency, but
even at high doses it is unable to reduce kidney swelling to the extent of
Rapa (MO morpholino oligonucleotide). k Fluorescent image of an
embryo 3 h after injection of rhodamine dextran into the heart.
Fluorescence disperses throughout the circulation. k′ The same embryo
24 h after injection shows the complete absence of fluorescence as it has
all been evacuated by the kidney. l Fluorescent dextran perfuses
systemically throughout the ift80 morphant to the same extent as
controls 3 h after injection. l′ The same embryo 24 h after injection still
has residual fluorescence in the circulation. m, m′ Close-up of the heart
of a control zebrafish showing the elimination of fluorescence after
24 h. n, n′ Persistence of fluorescence after 24 h in ift80 morphants,
particularly in the pronephros (arrowhead). o, o′ treatment with Rapa
reduces the residual fluorescence in morphants, particularly in the heart,
but some still persists in the pronephros (arrowhead). p, p′ treatment
with Rosc also partially rescues the filtering defect but less so than Rapa
(arrowhead). q Graph quantifying the percentage of original fluores-
cence remaining in the kidney 24 h after injection. Addition of drugs
has no effect on control embryos. Fluorescence is reduced to a similar
level as that in untreated ift80 and bbs4 morphants, but both drugs have
a slightly more marked effect on bbs4 than ift80 morphants. This graph
also shows that Rapa is more effective than Rosc in this system. In all
graphs, error bars represent the standard error of the mean (n≥10
embryos in all cases). Bars (a–h) 1 mm, (k–l′) 1 mm, (m–p′) 100 μm
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quickly as in the controls (Fig. 1l). Despite cardiac oedema
in the morphants, the heart beat at the same rate and with
the contractile force as in the controls (data not shown).
Treatment with rapamycin was able to partially rescue
the filtering capacity of the kidney, as evidenced by a faint
fluorescence remaining in the heart and pronephros 24 h
post-injection (Fig. 1o,o′). When roscovitine was added to
these morphants, there was also a significant reduction in
retained dextran compared to untreated fish, but there was
more residual fluorescence in the heart and pronephros than
in rapamycin-treated embryos (Fig. 1p,p′). Therefore,
roscovitine is not as effective at restoring renal function in
the morphant as rapamycin.
These functional assays were repeated using bbs4
morphants (and nphp2, not shown), as another example of
a ciliopathy gene causing a different disease when mutated
in humans. Figure 1q shows the amount of fluorescence
remaining in the heart 24 h post-injection: 9% of the
dextran remains in the controls, but in both ift80 and bbs4
morphants, only about 55% is removed. Rapamycin had no
effect on kidney function in the controls, but it did improve
filtering capacity by approximately 2.3-fold and approxi-
mately threefold in ift80 and bbs4 morphants, respectively,
as calculated by comparing the amount of fluorescence
remaining in the heart with or without drug treatment.
The addition of roscovitine improved filtering capacity
by approximately 1.2-fold and approximately 1.8-fold in
ift80 and bbs4 morphants, respectively. These data suggest
that the bbs4 morphant kidney phenotype is less severe than
the ift80 one as the function is restored to a greater extent. It
also suggests that rapamycin is twice as effective at
restoring renal function in zebrafish as roscovitine.
Rapamycin had a greater effect on functional restoration
when added at 24 hpf than at 4 hpf.
Discussion
The studies reported here validate the zebrafish as a model for
human ciliopathies. As there is currently a shortage of mouse
models for ciliopathies, many of which suffer from embryonic
lethality, have variable temporal cyst development and,
moreover, must often be euthanised and sectioned to reveal
the cysts, it is far more efficient to screen the phenotypes in the
fish [13]. We have demonstrated the virtue of the fish as a
preclinical drug screening tool capable of quantitatively
differentiating between the efficacy of two different com-
pounds, with the potential to assay functional repair as well
as morphological rescue. We have also observed similar
levels of renal structural and functional repair with another
known anti-cyst drug, paclitaxel (data not shown).
Renal disease is the greatest contributor to morbidity and
mortality in ciliopathy patients [2]. However, as the
ciliopathies are rare diseases with relatively few patients,
there is little commercial incentive to develop orphan drugs
and perform clinical trials. Nevertheless, it is important to
develop therapies to treat these patients. This preliminary
study provides proof of principle for a high-throughput
screen using a small-molecule library to identify more
compounds. These can then be tested on mouse models
with the ultimate aim of treating ciliopathy patients. The
approach also validates the use of pre-existing therapies for
new diseases that may have similar pathomechanisms to
polycystic kidney disease.
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